Breaking News, Collaborations & Alliances

Merck & Blackstone Enter Research and Development Funding Agreement 

Strategic financing will advance development of sac-TMT while Merck continues to progress its expansive pipeline.

By: Rachel Klemovitch

Assistant Editor

Merck (MSD outside of the United States and Canada) has agreed to receive funds managed by Blackstone Life Sciences (Blackstone) for the development of sacituzumab tirumotecan (sac-TMT). Sac-TMT is an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells. Merck is currently evaluating sac-TMT in 15 global Phase 3 clinical trials spanning six tumor types, including breast, endometrial, and lung...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters